Regentis Biomaterials Ltd. cash flow statement RGNT
In fiscal 2025, which ended Dec 31, 2025, Regentis Biomaterials Ltd. used $1.4 million of cash from operations.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
|---|---|
| Operating | |
| Stock-based compensation |
7
|
| Operating cash flow |
-1
|
| Financing | |
| Short-term debt issued |
0
|
| Financing cash flow |
9
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
- Listed as
- RGNT (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Or Akiva
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1912966
Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
- Intuitive Surgical Inc ISRG
- Edwards Lifesciences Corp EW
- STERIS plc STE
- Zimmer Biomet Holdings, Inc. ZBH
- Smith & Nephew PLC SNN
- Align Technology Inc ALGN
- MSA Safety Inc MSA
- Establishment Labs Holdings Inc. ESTA
All 29 Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.